Osteoarthritis in older cats: long-term low-dose meloxicam, including in stable CKD — MAYBE (weak evidence)

In older cats with osteoarthritis, including cats with stable chronic kidney disease, does long-term low-dose meloxicam improve mobility vs placebo without worsening renal function?

Shelf #196 · gate-verified and approved by the developer

MAYBE (weak evidence): There is no placebo-controlled trial of long-term low-dose meloxicam in cats on this shelf — the question as posed (vs placebo) has not been tested in a randomised trial in the records carded. What exists is a prospective uncontrolled study (Gunew 2008: 40 cats completing a mean 5.8 months at 0.01-0.03 mg/kg daily, owners rating efficacy good or excellent in 34/40, no deleterious effect on renal function detected) and two retrospective Gowan studies in cats older than 7 years, including cats with stable CKD, which found no difference in renal progression versus matched untreated controls and no apparent reduction in lifespan on meloxicam. That base can support cautious use in stable cats; it cannot establish efficacy against placebo or exclude renal harm — the stamp and this wording say so on the face. Drafted Nov 10, 2026 (VetMed build, topic #196); all figures from abstracts fetched and verified at drafting.

Gunew 2008: long-term low-dose meloxicam was palatable and owners rated efficacy good or excellent in 34/40 cats — with no control group

Prospective uncontrolled study (no placebo or comparator group)

Who: Cats: 40 cats diagnosed with osteoarthritis completing the trial (46 started) at a feline practice in Australia, given oral meloxicam at 0.01-0.03 mg/kg once daily with food, mean treatment duration 5.8 months. The record's publication type is 'Controlled Clinical Trial' but the abstract describes a prospective single-group study with no placebo or comparator arm.

Result: Gastrointestinal upset in 2/46 (4%) cats was the only adverse effect noted. No deleterious effect on renal function was detected in cats studied. Owners subjectively assessed treatment efficacy as good or excellent in 34/40 (85%) of cases.

Watch out: No placebo, no blinding and no comparator: owner ratings in an uncontrolled study cannot separate drug effect from placebo-by-proxy and natural fluctuation, and 40 cats cannot exclude uncommon renal harm.

Gunew MN, Menrath VH, Marshall RD. Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats. J Feline Med Surg. 2008;10(3):235-241. PMID: 18440263. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents, Non-Steroidal · Cat Diseases · Cats · Cyclooxygenase Inhibitors · Dose-Response Relationship, Drug · Female · Male · Meloxicam · Osteoarthritis · Thiazines · Thiazoles · Treatment Outcome

Gowan 2011: in cats with degenerative joint disease, long-term meloxicam was not associated with faster renal progression than in matched untreated controls — retrospectively

Retrospective case-control study

Who: Cats: 38 cats older than 7 years with degenerative joint disease at a feline-only practice (records 2005-2009) treated with meloxicam for more than 6 months — 22 with stable CKD at the start (IRIS stage 1: eight cats; stage 2: 13; stage 3: one) and 16 initially non-renal — compared with age- and IRIS-matched control cats not receiving meloxicam. Median maintenance dose after titration was 0.02 mg/kg/day in both groups (range 0.015-0.033); median treatment duration 467 days (renal group) and 327 days (non-renal group).

Result: There was no difference in sequential serum creatinine concentration or urine specific gravity measurements between the non-renal group treated with meloxicam compared to control cats not treated with meloxicam. There was less progression of renal disease in the renal group treated with meloxicam compared to the age- and IRIS-matched cats with CKD not given meloxicam. The authors conclude that prospective studies are required to confirm these findings.

Watch out: Retrospective and case-control by the record's own indexing: cats chosen for long-term meloxicam were clinically stable to begin with, so selection bias can explain part or all of the reassuring renal picture. This is not placebo-controlled efficacy evidence.

Gowan RA, Lingard AE, Johnston L et al. Retrospective case-control study of the effects of long-term dosing with meloxicam on renal function in aged cats with degenerative joint disease. J Feline Med Surg. 2011;13(10):752-761. PMID: 21906984. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents, Non-Steroidal · Case-Control Studies · Cat Diseases · Cats · Female · Kidney Function Tests · Male · Meloxicam · New South Wales · Osteoarthritis · Renal Insufficiency, Chronic · Retrospective Studies · Thiazines · Thiazoles

Gowan 2012: long-term meloxicam did not appear to shorten lifespan in aged cats with or without CKD — a retrospective safety observation, not a survival benefit

Retrospective analysis

Who: Cats: aged cats (older than 7 years) from the databases of two feline-only clinics, treated continuously with meloxicam for longer than 6 months, with complete medical records, grouped by whether overt chronic kidney disease was present at the initiation of therapy.

Result: The median longevity in the renal group was 18.6 years [95% confidence interval (CI) 17.5-19.2] and in the non-renal group 22 years [95% CI 18.5-23.8]. The median longevity after diagnosis of CKD was 1608 days [95% confidence interval 1344-1919]. In both groups the most common cause of death was neoplasia. The authors state that long-term treatment with oral meloxicam did not appear to reduce the lifespan of cats with pre-existent stable CKD, even for cats in IRIS stages II and III.

Watch out: Retrospective longevity analysis with no randomised comparator: 'did not appear to reduce lifespan' is a safety observation in selected, stable cats — it is not a claim that meloxicam prolongs life, and this pack makes no survival-benefit claim (hence tierC is false).

Gowan RA, Baral RM, Lingard AE et al. A retrospective analysis of the effects of meloxicam on the longevity of aged cats with and without overt chronic kidney disease. J Feline Med Surg. 2012;14(12):876-881. PMID: 22821331. Registry ID: none in the record. MeSH: Animals · Anti-Inflammatory Agents, Non-Steroidal · Australia · Cat Diseases · Cats · Kidney Function Tests · Longevity · Meloxicam · Osteoarthritis · Renal Insufficiency, Chronic · Retrospective Studies · Risk Factors · Thiazines · Thiazoles

Synthesis: cautious-use safety signals from observational data; efficacy vs placebo untested

Synthesis

Who: Synthesis of the cards above: Gunew 2008 (prospective uncontrolled study, 40 cats completing), Gowan 2011 (retrospective case-control study, 38 treated cats) and Gowan 2012 (retrospective longevity analysis, two feline-only clinics).

Result: No card here is a randomised or placebo-controlled trial. The prospective study shows low-dose meloxicam (median maintenance 0.02 mg/kg/day in the retrospective cohort) is palatable and owner-rated as helpful in most cats; the two retrospective studies are reassuring that, in older cats selected as clinically stable — including IRIS stage 1-3 CKD — long-term treatment was not associated with faster renal progression or shorter lifespan than in matched untreated cats. Selection of stable cats into treatment is exactly the bias these designs cannot remove, which is why the shelf stamp is MAYBE (weak evidence) and why the efficacy half of the question remains unanswered by trial evidence.

Watch out: Do not read the retrospective renal reassurance as proof of renal safety for unstable, dehydrated or advanced-CKD cats: the treated cats were stable at initiation, and the authors of the case-control study themselves call for prospective confirmation.

Synthesis of Gunew MN et al. PMID: 18440263; Gowan RA et al. PMID: 21906984; Gowan RA et al. PMID: 22821331. Registry IDs as on the individual cards.

Back to the library index · VetMed home

VetMed is an educational resource, not veterinary advice.